Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement
- 1 April 2020
- journal article
- research article
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 15 (4) , 1551-1560
Abstract
In the South Korean health technology assessment system, prices of alternative medicines, incremental cost effectiveness ratios in pharmaco-economic evaluations and patient access improvement systems such as risk-sharing agreements are the most important factors concerning the reimbursement of regenerative medicine (RM). Research and development companies in RM should review the key features of these medicines throughout the product development cycle to increase the probability of successful reimbursement. In addition, the South Korean government should take steps to improve the system to reflect the unique characteristics and value of RM in the reimbursement and pricing policy, to revitalize research and development, and increase patient access.Keywords
This publication has 32 references indexed in Scilit:
- Eight-year experience of using HTA in drug reimbursement: South KoreaHealth Policy, 2016
- REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCEMedical Law Review, 2016
- Target prices for mass production of tyrosine kinase inhibitors for global cancer treatmentBMJ Open, 2016
- Bringing Regenerative Medicines to the Clinic: The Future for Regulation and ReimbursementRegenerative Medicine, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Orphan drugs expenditure in the Netherlands in the period 2006–2012Orphanet Journal of Rare Diseases, 2014
- Cancer Drugs in the United States: Justum Pretium—The Just PriceJournal of Clinical Oncology, 2013
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet Journal of Rare Diseases, 2012
- Evaluation on the first 2 years of the positive list system in South KoreaHealth Policy, 2012
- Achieving Reimbursement for Regenerative Medicine Products in the USARegenerative Medicine, 2010